Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1240493 | 1.00 | F2RL3 (0.43) | F2RL3CHRNB4CHRNA3CHRNB1CHRNB2 | |
| SCHEMBL1241581 | 0.83 | F2RL3 (0.47) | F2RL3CHRNB4CHRNA3CHRNB1CHRNB2 | |
| SCHEMBL1240615 | 0.83 | F2RL3 (0.47) | F2RL3CHRNB4CHRNA3CHRNB1CHRNB2 | |
| SCHEMBL1240420 | 0.82 | F2RL3 (0.43) | F2RL3CHRNB4CHRNA3CHRNB1CHRNB2 | |
| SCHEMBL1240418 | 0.82 | F2RL3 (0.43) | F2RL3CHRNB4CHRNA3CHRNB1CHRNB2 | |
| SCHEMBL1241531 | 0.82 | CHRNB4 (0.36) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL1240516 | 0.82 | CHRNB4 (0.36) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL1241510 | 0.82 | CHRNB4 (0.36) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL1238449 | 0.82 | CHRNB4 (0.36) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL1238444 | 0.82 | CHRNB4 (0.36) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2011016234-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142691-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | F2RL3 3167/4885CHRNB4 383/4885CHRNA3 231/4885 |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | F2RL3 3167/4885CHRNB4 383/4885CHRNA3 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.